Page 119 - Read Online

Page 10 of 13 Best et al. Hepatoma Res 2020;6:62 I http://dx.doi.org/10.20517/2394-5079.2020.56

In the near future, the combination of standard of care ultrasound and biomarker-based screening
approaches seem to be the next step to increase sensitivity and specificity of HCC surveillance.

Among the efforts of optimizing screening algorithms, the education of gate keepers such as primary care
physicians, health care associates, and also the population at risk per se is another pivotal factor to increase
the rate of HCC early detection.

DECLARATIONS
Authors’ contributions
Conception or design of the work: Best J, Bechmann LP
Drafting the article: Best J, Sydor S
Final approval of the version to be published: Best J, Sydor S, Bechmann LP, Canbay A
Critical revision of the article: Bechmann LP, Canbay A

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27.
2. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology
2014;60:1767-75.
3. Rich NE, Hester C, Odewole M, Murphy CC, Parikh ND, et al. Racial and ethnic differences in presentation and outcomes of
hepatocellular carcinoma. Clin Gastroenterol Hepatol 2019;17:551-9.e1.
4. De Minicis S, Agostinelli L, Rychlicki C, Sorice GP, Saccomanno S, et al. HCC development is associated to peripheral insulin resistance
in a mouse model of NASH. PLoS One 2014;9:e97136.
5. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on
systematic review. Clin Gastroenterol Hepatol 2012;10:1342-59.e2.
6. Ertle J, Dechene A, Sowa JP, Penndorf V, Herzer K, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the
absence of apparent cirrhosis. Int J Cancer 2011;128:2436-43.
7. Kudo M. Early detection and curative treatment of early-stage hepatocellular carcinoma. Clin Gastroenterol Hepatol 2005;3:S144-8.
8. Weinmann A, Koch S, Niederle IM, Schulze-Bergkamen H, Konig J, et al. Trends in epidemiology, treatment, and survival of
hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry. J Clin Gastroenterol
2014;48:279-89.
9. Shah SA, Smith JK, Li Y, Ng SC, Carroll JE, et al. Underutilization of therapy for hepatocellular carcinoma in the medicare population.
Cancer 2011;117:1019-26.
10. Sonnenday CJ, Dimick JB, Schulick RD, Choti MA. Racial and geographic disparities in the utilization of surgical therapy for
hepatocellular carcinoma. J Gastrointest Surg 2007;11:1636-46; discussion 46.